HDAC9 and non-small cell lung carcinoma: Although some histone deacetylase (HDAC) inhibitors, such as Vorinostat and Panobinostat, have gained optimistic results in pre-clinical and clinical trials on NSCLC, further studies of HDAC inhibitors in lung cancer are necessary for evaluating their anti-tumor effect [16, 23].